US pharmacy deals could cut costs of AbbVie and Gilead's HCV treatments

January 6, 2015 2:24 PM

8 0

US pharmacy deals could cut costs of AbbVie and Gilead's HCV treatments

A number of new drugs for the estimated 3.2 million people in the US living with chronic Hepatitis C virus infection have been launched over the past year, with Abbvie’s drug, Viekira Pak, the latest following its approval by the US Food and Drug Administration (FDA) last month.

The drug combines three active pharmaceutical ingredients (API): an NS5A inhibitor, ombitasvir; NS3/4A protease inhibitor, paritaprevir; and non-nucleoside NS5B polymerase inhibitor, ritonavir.

Read more

To category page

Loading...